Literature DB >> 36129600

ERK/HIF-1α/VEGF pathway: a molecular target of ELABELA (ELA) peptide for attenuating cardiac ischemia-reperfusion injury in rats by promoting angiogenesis.

Kamran Rakhshan1, Masoomeh Sharifi2,3, Fatemeh Ramezani2, Yaser Azizi2,3, Nahid Aboutaleb4,5.   

Abstract

BACKGROUND: Myocardial ischemia-reperfusion (I/R) injury is caused by a chain of events such as endothelial dysfunction. This study was conducted to investigate protective effects of ELABELA against myocardial I/R in Wistar rats and clarify its possible mechanisms. METHODS AND 
RESULTS: MI model was established based on the left anterior descending coronary artery ligation for 30 min. Then, 5 µg/kg of ELA peptide was intraperitoneally infused in rats once per day for 4 days. Western blot assay was used to assay the expression of t-ERK1/2, and p-ERK1/2 in different groups. The amount of myocardial capillary density, the expression levels of VEGF and HIF-1α were evaluated using immunohistochemistry assay. Masson's trichrome staining was utilized to assay cardiac interstitial fibrosis. The results showed that establishment of MI significantly enhanced cardiac interstitial fibrosis and changed p-ERK1/2/ t-ERK1/2 ratio. Likewise, ELA post-treatment markedly increased myocardial capillary density, the expression of several angiogenic factors (VEGF-A, HIF-1α), and reduced cardiac interstitial fibrosis by activation of ERK1/2 signaling pathways.
CONCLUSION: Collectively, ELA peptide has ability to reduce myocardial I/R injury by promoting angiogenesis and reducing cardiac interstitial fibrosis through activating ERK/HIF-1α/VEGF pathway.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Angiogenesis; ELABELA peptide; Fibrosis; Myocardial ischemia/reperfusion

Year:  2022        PMID: 36129600     DOI: 10.1007/s11033-022-07818-y

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.742


  48 in total

Review 1.  Angiogenic growth factors in myocardial infarction: a critical appraisal.

Authors:  Hemalatha Thiagarajan; UmaMaheswari Thiyagamoorthy; Iswariya Shanmugham; Gunadharini Dharmalingam Nandagopal; Anbukkarasi Kaliyaperumal
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

Review 2.  Myocardial ischemia-reperfusion injury and the influence of inflammation.

Authors:  M Algoet; S Janssens; U Himmelreich; W Gsell; M Pusovnik; J Van den Eynde; W Oosterlinck
Journal:  Trends Cardiovasc Med       Date:  2022-02-16       Impact factor: 6.677

Review 3.  ROS and redox signaling in myocardial ischemia-reperfusion injury and cardioprotection.

Authors:  Susana Cadenas
Journal:  Free Radic Biol Med       Date:  2018-01-31       Impact factor: 7.376

4.  Activation of hypoxia response in endothelial cells contributes to ischemic cardioprotection.

Authors:  Risto Kerkelä; Sara Karsikas; Zoltan Szabo; Raisa Serpi; Johanna Magga; Erhe Gao; Kari Alitalo; Andrey Anisimov; Raija Sormunen; Ilkka Pietilä; Laura Vainio; Walter J Koch; Kari I Kivirikko; Johanna Myllyharju; Peppi Koivunen
Journal:  Mol Cell Biol       Date:  2013-06-17       Impact factor: 4.272

5.  Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association.

Authors:  Salim S Virani; Alvaro Alonso; Hugo J Aparicio; Emelia J Benjamin; Marcio S Bittencourt; Clifton W Callaway; April P Carson; Alanna M Chamberlain; Susan Cheng; Francesca N Delling; Mitchell S V Elkind; Kelly R Evenson; Jane F Ferguson; Deepak K Gupta; Sadiya S Khan; Brett M Kissela; Kristen L Knutson; Chong D Lee; Tené T Lewis; Junxiu Liu; Matthew Shane Loop; Pamela L Lutsey; Jun Ma; Jason Mackey; Seth S Martin; David B Matchar; Michael E Mussolino; Sankar D Navaneethan; Amanda Marma Perak; Gregory A Roth; Zainab Samad; Gary M Satou; Emily B Schroeder; Svati H Shah; Christina M Shay; Andrew Stokes; Lisa B VanWagner; Nae-Yuh Wang; Connie W Tsao
Journal:  Circulation       Date:  2021-01-27       Impact factor: 29.690

6.  FUNDC1 activates the mitochondrial unfolded protein response to preserve mitochondrial quality control in cardiac ischemia/reperfusion injury.

Authors:  Haizhe Ji; Jin Wang; David Muid; Wei Song; Yinong Jiang; Hao Zhou
Journal:  Cell Signal       Date:  2022-01-17       Impact factor: 4.315

Review 7.  Novel cardioprotective and regenerative therapies in acute myocardial infarction: a review of recent and ongoing clinical trials.

Authors:  Nicholas B Spath; Nicholas L Mills; Nicholas L Cruden
Journal:  Future Cardiol       Date:  2016-10-28

8.  Comparison of myocardial microcirculatory perfusion after catheter-administered intracoronary thrombolysis with anisodamine versus standard thrombus aspiration in patients with ST-elevation myocardial infarction.

Authors:  Yang Fu; Xin-Shun Gu; Guo-Zhen Hao; Yun-Fa Jiang; Wei-Ze Fan; Yan-Ming Fan; Qing-Min Wei; Xiang-Hua Fu; Yong-Jun Li
Journal:  Catheter Cardiovasc Interv       Date:  2019-02-17       Impact factor: 2.692

9.  Apelin signaling drives vascular endothelial cells toward a pro-angiogenic state.

Authors:  Christian Sm Helker; Jean Eberlein; Kerstin Wilhelm; Toshiya Sugino; Julian Malchow; Annika Schuermann; Stefan Baumeister; Hyouk-Bum Kwon; Hans-Martin Maischein; Michael Potente; Wiebke Herzog; Didier Yr Stainier
Journal:  Elife       Date:  2020-09-21       Impact factor: 8.140

Review 10.  Coronary microvascular injury in myocardial infarction: perception and knowledge for mitochondrial quality control.

Authors:  Xing Chang; Amanda Lochner; Hsueh-Hsiao Wang; Shuyi Wang; Hang Zhu; Jun Ren; Hao Zhou
Journal:  Theranostics       Date:  2021-05-03       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.